Nachrichten zur Hims & Hers Health Inc. Aktie

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection…

The telehealth company will begin shipping the blockbuster weight loss drug directly to customers…

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug…

BofA raised the firm’s price target on Hims Hers (HIMS) to $26 from $22 and keeps an Underperform rating…

Hims & Hers Health Inc.’s (HIMS) stock surged 35% to $38.39 after announcing a collaboration with Novo Nordisk to offer…

Frankfurt (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von XTB: Die Experten von XTB nehmen die Aktie von Novo Nordisk A/S (ISIN: DK0062498333, WKN:…

Hims & Hers Health surged after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a…

New York (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von TD Cowen: 1. Positive Aspekte Starkes erstes Quartal: Hims & Hers Health Inc.…

New York (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von Morgan Stanley: 1. Positive Aspekte - Solide Geschäftsentwicklung: Umfragedaten deuten auf stabile fundamentale…

Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer…

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer…

The partnership will start off by giving Hims & Hers users direct access to NovoCare, the drugmakers direct-to-consumer platform....…

Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk…

Hims & Hers Health (HIMS) stock surged 43% on a new partnership with Novo Nordisk (NVO) which boosts access to…

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk…

Hims & Hers just rebounded massively after its partnership with Novo Nordisk. is this the right time to buy HIMS…

Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with…

Der Adipositas-Markt bleibt mächtig in Bewegung: Kein geringerer als Novo Nordisk arbeitet fortan mit Hims & Hers zusammen. Ausgerechnet mit…

Der Adipositas-Markt bleibt mächtig in Bewegung: Kein geringerer als Novo Nordisk arbeitet fortan mit Hims & Hers zusammen. Ausgerechnet mit…

Hims & Hers stock surges on Novo Nordisk collaboration…

Danish drugmaker Novo Nordisk has partnered with Hims & Hers Healths to sell its popular weight loss drug through a…

Customers will get access to the offerings of all dose strengths of Wegovy and a membership at a price starting…

Hims & Hers stock surges on Novo Nordisk collaboration…

Hims & Hers Health has an average rating of hold and mean price target of $44.20, according to analysts…

Danish drugmaker Novo Nordisk has partnered with Hims & Hers Healths to sell its popular weight loss drug through a bundled offering…

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo…

Hims & Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss…

Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity…

SAN FRANCISCO--(BUSINESS WIRE)--Apr 29, 2025--…

SAN FRANCISCO--(BUSINESS WIRE)--Apr 29, 2025--…

A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a…

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their…

Hims & Hers stock valuation remains high despite performance.…

Novo Nordisk partners with Hims, Ro, and LifeMD to expand Wegovy access as compounding rules tighten and global reach grows.…

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14%…

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $28.10, with a -0.14% movement compared to the…

Hims & Hers Health may face an incrementally neutral to slightly negative impact from a recent US court decision…

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14%…

The FDA issued a warning about adverse effects related to a popular hair loss product available through telehealth platforms like…

Citi lowered the firm’s price target on Hims Hers to $25 from $27 and keeps a Sell rating on…

These hair aid products, which are in spray and serum formats, are not approved by the FDA but they are…

…